Idroquark (Hydrochlorothiazide, Ramipril)

Hydrochlorothiazide increases urine output by inhibiting sodium‑chloride reabsorption, lowering plasma volume. Ramipril blocks the conversion of angiotensin I to angiotensin II, causing vasodilation and reducing aldosterone. Together they lower blood pressure through complementary mechanisms of volume reduction and vascular relaxation.

The specific dose of Idroquark is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and other individual factors. Dosage adjustments are made according to clinical guidelines and patient monitoring.

Idroquark is classified as pregnancy category D, indicating evidence of fetal risk, and it should be avoided unless the potential benefit justifies the risk. Use while breastfeeding is not recommended because the drugs can pass into breast milk and affect the infant.

To place an order, submit an enquiry on the Idroquark product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent therapies, Idroquark offers the convenience of two complementary mechanisms in one tablet, often achieving better blood‑pressure control than either component alone. It may reduce the need for multiple pills, but clinicians must consider individual tolerability and interaction profiles when choosing therapy.

Idroquark should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from excess moisture and direct sunlight to maintain stability and potency throughout its shelf life.

Idroquark is taken orally, usually once daily or as directed by the prescriber. It should be swallowed whole with a glass of water, and patients are advised to follow any specific timing recommendations related to meals or other medications.

The most serious risks include angioedema, which can cause swelling of the face or throat, severe hypotension that may lead to fainting, acute kidney injury, and dangerous elevations in blood potassium levels. Patients should seek immediate medical attention if they experience any of these symptoms.

Idroquark is contraindicated in patients with known hypersensitivity to either component, those with severe renal impairment, hyperkalemia, or a history of angioedema related to ACE‑inhibitor therapy. It should also be avoided in pregnant women and used with caution in the elderly.